SAN DIEGO, Feb. 10, 2021 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced today
that the company will release financial results for the fourth
quarter and year-end 2020, after the market close on Wednesday, February 17, 2021.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 17,
2021. To participate on the conference call, please dial
(844) 850-0543 from the U.S. or (412) 317-5199 from outside the
U.S. In addition, following the completion of the call, a telephone
replay will be accessible until February 24,
2021 by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering conference ID
#10150687. Those interested in listening to the conference
call live via the internet may do so by visiting the Webcasts page
of Viking's website at http://ir.vikingtherapeutics.com/webcasts.
An archive of the webcast will also be available on the Webcasts
page of the company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2 trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1 first-in-human clinical trial. The
company holds exclusive worldwide rights to a portfolio of five
therapeutic programs, including those noted above, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2020-on-february-17-2021-301226161.html
SOURCE Viking Therapeutics, Inc.